Dana Investment Advisors Inc. Sells 36,261 Shares of Pfizer Inc. $PFE

Dana Investment Advisors Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 35.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 66,811 shares of the biopharmaceutical company’s stock after selling 36,261 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Pfizer were worth $1,702,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer in the third quarter worth about $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer during the 2nd quarter valued at about $30,000. True Wealth Design LLC raised its stake in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the second quarter worth about $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in Pfizer in the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PFE. Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Morgan Stanley reduced their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $27.70.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants full approval to Pfizer’s BRAFTOVI regimen for metastatic colorectal cancer — expands label to first‑line use, supporting upside to oncology sales and the “bull case” narratives for PFE. Pfizer’s Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment
• Positive Sentiment: Analyses argue the BRAFTOVI approval could re‑shape Pfizer’s growth outlook in oncology, providing a clear revenue catalyst if uptake in first‑line mCRC is strong. The Bull Case For Pfizer (PFE) Could Change Following New First-Line BRAFTOVI Colorectal Cancer Approval
• Positive Sentiment: Pfizer secures rights to a new GLP‑1 candidate as the company broadens its obesity pipeline — a strategic move to chase a large market and diversify future revenue streams. Pfizer secures rights to new GLP-1 as obesity push gathers pace
• Neutral Sentiment: Dividend narrative remains supportive: articles highlighting Pfizer’s 6%+ yield and retiree flows into dividend funds underscore investor appetite for PFE income, which can stabilize the stock. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.
• Neutral Sentiment: Zacks upgraded Pfizer from “strong sell” to “hold,” a modest positive signal but not a bullish re‑rating; it may temper short‑term selling. Zacks.com
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of an “insurmountable” $15B–$20B revenue decline through 2030 — a bearish structural thesis that could cap valuation upside. RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study — a pipeline setback that reduces optionality in immunology and may modestly pressure sentiment. Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study

Pfizer Trading Up 0.1%

PFE opened at $27.11 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a market capitalization of $154.14 billion, a price-to-earnings ratio of 19.93 and a beta of 0.47. The business has a fifty day moving average price of $26.08 and a 200 day moving average price of $25.39. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the business posted $0.63 EPS. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. Pfizer’s dividend payout ratio is currently 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.